Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Mar;25(3):395–397. doi: 10.1128/aac.25.3.395

Ceftazidime in the treatment of pediatric patients with severe urinary tract infections due to Pseudomonas spp.

F Rusconi, B M Assael, A Florioli, G Zaffaroni
PMCID: PMC185530  PMID: 6372686

Abstract

Fifteen pediatric patients with complicated urinary tract infections due to Pseudomonas spp. were treated for 10 to 18.5 days with ceftazidime administered intramuscularly twice daily. Urine sterilization during therapy was obtained in all patients. Three patients had relapses which were cured with a second course of ceftazidime. Minor liver damage, eosinophilia, and Candida superinfection developed in one patient each.

Full text

PDF
395

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chang C. T., Khan A. J., Agbayani M. M., Jhaveri R., Amin I., Evans H. E. Pharmacokinetics and safety of cefamandole in infants and children. Antimicrob Agents Chemother. 1978 Dec;14(6):838–841. doi: 10.1128/aac.14.6.838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clumeck N., Gordts B., Dab I., Jaspar N., Van Laethem Y., Butzler J. P. Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):207–211. doi: 10.1093/jac/12.suppl_a.207. [DOI] [PubMed] [Google Scholar]
  3. Gozzard D. I., Geddes A. M., Farrell I. D., Eykyn S. J., Phillips I., Wise R., Brown R. M. Ceftazidime--a new extended-spectrum cephalosporin. Lancet. 1982 May 22;1(8282):1152–1156. doi: 10.1016/s0140-6736(82)92228-0. [DOI] [PubMed] [Google Scholar]
  4. Knirsch A. K., Gralla E. J. Abnormal serum transaminase levels after parenteral ampicillin and carbenicillin administration. N Engl J Med. 1970 May 7;282(19):1081–1082. doi: 10.1056/NEJM197005072821907. [DOI] [PubMed] [Google Scholar]
  5. Neu H. C., Labthavikul P. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Jan;21(1):11–18. doi: 10.1128/aac.21.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Padoan R., Brienza A., Crossignani R. M., Lodi G., Giunta A., Assael B. M., Granata F., Passarella E., Vallaperta P. A., Xerri L. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. J Pediatr. 1983 Aug;103(2):320–324. doi: 10.1016/s0022-3476(83)80377-1. [DOI] [PubMed] [Google Scholar]
  7. STAMEY T. A., GOVAN D. E., PALMER J. M. THE LOCALIZATION AND TREATMENT OF URINARY TRACT INFECTIONS: THE ROLE OF BACTERICIDAL URINE LEVELS AS OPPOSED TO SERUM LEVELS. Medicine (Baltimore) 1965 Jan;44:1–36. doi: 10.1097/00005792-196501000-00001. [DOI] [PubMed] [Google Scholar]
  8. Siegel S. R., Sokoloff B., Siegel B. Asymptomatic and symptomatic urinary tract infection in infancy. Am J Dis Child. 1973 Jan;125(1):45–47. doi: 10.1001/archpedi.1973.04160010025006. [DOI] [PubMed] [Google Scholar]
  9. Verbist L. Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli. Antimicrob Agents Chemother. 1981 Mar;19(3):407–413. doi: 10.1128/aac.19.3.407. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES